Other Clinical Trial - Post-Authorization Safety, Tolerability &

Updated 06/21/2024

Status Completed

Clinical Trial Summary

The purpose of the study is to acquire additional data on safety, tolerability and immunogenicity of HyQvia in pediatric (age two to <18 years) patients with Primary Immunodeficiency Diseases (PIDD)

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Immunologic Deficiency Syndromes
Primary Immunodeficiency Diseases
Primary Immunodeficiency Diseases (PID)

Clinical Trial Details

NCT number	NCT03116347
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 4
Start date	May 30, 2017
Completion date	January 15, 2021

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03277313` - Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects	Phase 3
	Completed	`NCT03716700` - Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobulin (CANCUN)
	Active, not recruiting	`NCT05513586` - A Study to Evaluate the Long-term Safety of TAK-771 in Japanese Primary Immunodeficiency Disease (PID) Participants	Phase 3
	Recruiting	`NCT05986734` - Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies
	Completed	`NCT00546871` - Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects	Phase 2/Phase 3
	Recruiting	`NCT05755035` - A Study About How TAK-881 is Processed by the Body and Side Effects in People With Primary Immunodeficiency Diseases	Phase 2/Phase 3
	Completed	`NCT02593188` - Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global)
	Completed	`NCT00157079` - Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders	Phase 3
	Completed	`NCT01412385` - Immune Globulin Subcutaenous (Human), 20%	Phase 2/Phase 3
	Completed	`NCT00161993` - Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Patients With Primary Immunodeficiency (Hypo- or Agammaglobulinemia)	Phase 2
	Completed	`NCT01175213` - Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID	Phase 3
	Completed	`NCT01218438` - Phase 2/3 Study of IGSC, 20% in PIDD	Phase 2/Phase 3
	Completed	`NCT05150340` - A Study of TAK-771 in Japanese People With Primary Immunodeficiency Diseases (PID)	Phase 3
	Not yet recruiting	`NCT06076642` - A Study About the Long-Term Safety of TAK-881 in People With Primary Immunodeficiency Diseases	Phase 3
	Completed	`NCT00782106` - Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously	Phase 1/Phase 2
	Completed	`NCT01485796` - Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD	Phase 2/Phase 3
	Recruiting	`NCT06150534` - At-Home Subcutaneous Immunoglobulin Replacement Therapy Using Alexa Skill
	Completed	`NCT00814320` - Gammagard Liquid and rHuPH20 in PID	Phase 3
	Completed	`NCT04346108` - A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primary Immunodeficiency Diseases (PID)	Phase 3